StockMarketWire.com - Drug developer SalvaRX Group booked a deeper annual loss owing to an asset disposal.

Pre-tax losses for the year through December amounted to £3.4m, compared to losses of £2.2m on-year.

The loss came despite R&D spending falling to £861k, down from £1.19m on-year.


At 2:14pm: [LON:SALV] Salvarx Group Plc share price was -1.5p at 9p



Story provided by StockMarketWire.com